HK1171336A1 - 利用結合內皮素受體抑製劑治療腦轉移瘤 - Google Patents
利用結合內皮素受體抑製劑治療腦轉移瘤Info
- Publication number
- HK1171336A1 HK1171336A1 HK12112305.1A HK12112305A HK1171336A1 HK 1171336 A1 HK1171336 A1 HK 1171336A1 HK 12112305 A HK12112305 A HK 12112305A HK 1171336 A1 HK1171336 A1 HK 1171336A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- inhibitors
- treatment
- combination
- brain metastases
- chemotherapy agent
- Prior art date
Links
- 208000003174 Brain Neoplasms Diseases 0.000 title 1
- 102000010180 Endothelin receptor Human genes 0.000 title 1
- 108050001739 Endothelin receptor Proteins 0.000 title 1
- 206010059282 Metastases to central nervous system Diseases 0.000 title 1
- 239000012829 chemotherapy agent Substances 0.000 title 1
- 238000011393 cytotoxic chemotherapy Methods 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N5/1077—Beam delivery systems
- A61N5/1084—Beam delivery systems for delivering multiple intersecting beams at the same time, e.g. gamma knives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0622—Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0331—Animal model for proliferative diseases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/08—Coculture with; Conditioned medium produced by cells of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/30—Coculture with; Conditioned medium produced by tumour cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Environmental Sciences (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Neurosurgery (AREA)
- Toxicology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23268709P | 2009-08-10 | 2009-08-10 | |
PCT/US2010/044832 WO2011019630A2 (en) | 2009-08-10 | 2010-08-09 | Treatment of astrocytes-tumor cells with inhibitors of endothelin receptors |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1171336A1 true HK1171336A1 (zh) | 2013-03-28 |
Family
ID=42938154
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK12112305.1A HK1171336A1 (zh) | 2009-08-10 | 2012-11-29 | 利用結合內皮素受體抑製劑治療腦轉移瘤 |
Country Status (28)
Country | Link |
---|---|
US (2) | US8999934B2 (zh) |
EP (1) | EP2464218B1 (zh) |
JP (1) | JP2013501791A (zh) |
KR (1) | KR20120088665A (zh) |
CN (1) | CN102510719B (zh) |
AU (1) | AU2010282744B2 (zh) |
BR (1) | BR112012003103A2 (zh) |
CA (1) | CA2770397A1 (zh) |
CL (1) | CL2012000333A1 (zh) |
DK (1) | DK2464218T3 (zh) |
EA (1) | EA023864B1 (zh) |
ES (1) | ES2543280T3 (zh) |
HK (1) | HK1171336A1 (zh) |
HR (1) | HRP20150890T1 (zh) |
HU (1) | HUE026005T2 (zh) |
IL (1) | IL217915A0 (zh) |
IN (1) | IN2012DN01261A (zh) |
MA (1) | MA33571B1 (zh) |
MX (1) | MX2012001562A (zh) |
NZ (1) | NZ598078A (zh) |
PL (1) | PL2464218T3 (zh) |
PT (1) | PT2464218E (zh) |
SG (1) | SG178828A1 (zh) |
SI (1) | SI2464218T1 (zh) |
TN (1) | TN2012000054A1 (zh) |
TW (1) | TWI483938B (zh) |
WO (1) | WO2011019630A2 (zh) |
ZA (1) | ZA201200980B (zh) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2013008798A (es) * | 2011-02-04 | 2013-10-17 | Actelion Pharmaceuticals Ltd | Composiciones que comprenden macitentan para el tratamiento del glioblastoma multiforme. |
WO2012177624A2 (en) * | 2011-06-21 | 2012-12-27 | The Johns Hopkins University | Focused radiation for augmenting immune-based therapies against neoplasms |
US10238650B2 (en) | 2015-03-06 | 2019-03-26 | Beyondspring Pharmaceuticals, Inc. | Method of treating cancer associated with a RAS mutation |
US10076518B2 (en) * | 2015-03-06 | 2018-09-18 | Beyondspring Pharmaceuticals, Inc. | Method of treating a brain tumor |
US10695400B2 (en) | 2015-08-03 | 2020-06-30 | Enb Therapeutics, Inc. | Compositions and methods for treating cancers associated with ETBR activation |
JP6996728B2 (ja) * | 2016-01-07 | 2022-01-17 | 学校法人自治医科大学 | グルコーストランスポーター1発現用アデノ随伴ウイルスベクター |
RU2753543C1 (ru) | 2016-02-08 | 2021-08-17 | Бейондспринг Фармасьютикалс, Инк. | Композиции, содержащие тукаресол или его аналоги |
JP7122499B2 (ja) * | 2016-06-03 | 2022-08-22 | 幸久 村田 | がん転移阻害剤 |
WO2018129381A1 (en) | 2017-01-06 | 2018-07-12 | Beyondspring Pharmaceuticals, Inc. | Tubulin binding compounds and therapeutic use thereof |
JP2020514412A (ja) | 2017-02-01 | 2020-05-21 | ビヨンドスプリング ファーマシューティカルズ,インコーポレイテッド | 好中球減少症の低減方法 |
WO2019140324A1 (en) | 2018-01-12 | 2019-07-18 | Enb Therapeutics, Inc. | Deuterated compounds, compositions, and methods for treating cancers associated with etbr activation |
KR20200112881A (ko) | 2018-01-24 | 2020-10-05 | 비욘드스프링 파마수티컬스, 인코포레이티드. | 플리나불린의 투여를 통해 혈소판감소증을 감소시키는 조성물 및 방법 |
CN109232546B (zh) | 2018-09-25 | 2020-09-04 | 中国人民解放军总医院 | 一种嘧啶磺酰胺类衍生物的医药用途 |
CN112062857A (zh) * | 2019-06-10 | 2020-12-11 | 鸿运华宁(杭州)生物医药有限公司 | Eta抗体与bnp的融合蛋白质,及其药物组合物和应用 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0116237B8 (pt) * | 2000-12-18 | 2021-05-25 | Actelion Pharmaceuticals Ltd | "composto de sulfamida, composição farmacêutica contendo o mesmo e seu uso como medicamento antagonista de receptor de endotelina". |
GB0223854D0 (en) | 2002-10-12 | 2002-11-20 | Astrazeneca Ab | Therapeutic treatment |
US20050043233A1 (en) | 2003-04-29 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis |
US20060058311A1 (en) | 2004-08-14 | 2006-03-16 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
RU2424805C2 (ru) | 2005-09-12 | 2011-07-27 | Актелион Фармасьютиклз Лтд | Стабильные фармацевтические композиции, включающие пиримидинсульфамид |
JP5514123B2 (ja) | 2008-02-20 | 2014-06-04 | アクテリオン ファーマシューティカルズ リミテッド | 卵巣癌を治療するための、パクリタキセルを含む配合剤 |
MX2013008798A (es) | 2011-02-04 | 2013-10-17 | Actelion Pharmaceuticals Ltd | Composiciones que comprenden macitentan para el tratamiento del glioblastoma multiforme. |
-
2010
- 2010-08-09 JP JP2012524769A patent/JP2013501791A/ja not_active Ceased
- 2010-08-09 PL PL10742690T patent/PL2464218T3/pl unknown
- 2010-08-09 MX MX2012001562A patent/MX2012001562A/es active IP Right Grant
- 2010-08-09 NZ NZ598078A patent/NZ598078A/xx not_active IP Right Cessation
- 2010-08-09 EP EP10742690.0A patent/EP2464218B1/en not_active Not-in-force
- 2010-08-09 EA EA201270264A patent/EA023864B1/ru not_active IP Right Cessation
- 2010-08-09 HU HUE10742690A patent/HUE026005T2/en unknown
- 2010-08-09 IN IN1261DEN2012 patent/IN2012DN01261A/en unknown
- 2010-08-09 BR BR112012003103A patent/BR112012003103A2/pt not_active IP Right Cessation
- 2010-08-09 CN CN201080040990.1A patent/CN102510719B/zh not_active Expired - Fee Related
- 2010-08-09 US US13/390,072 patent/US8999934B2/en not_active Expired - Fee Related
- 2010-08-09 CA CA2770397A patent/CA2770397A1/en not_active Abandoned
- 2010-08-09 KR KR1020127006203A patent/KR20120088665A/ko not_active Application Discontinuation
- 2010-08-09 ES ES10742690.0T patent/ES2543280T3/es active Active
- 2010-08-09 PT PT107426900T patent/PT2464218E/pt unknown
- 2010-08-09 WO PCT/US2010/044832 patent/WO2011019630A2/en active Application Filing
- 2010-08-09 DK DK10742690.0T patent/DK2464218T3/en active
- 2010-08-09 SG SG2012009338A patent/SG178828A1/en unknown
- 2010-08-09 TW TW099126507A patent/TWI483938B/zh not_active IP Right Cessation
- 2010-08-09 AU AU2010282744A patent/AU2010282744B2/en not_active Ceased
- 2010-08-09 SI SI201031003T patent/SI2464218T1/sl unknown
-
2012
- 2012-02-02 IL IL217915A patent/IL217915A0/en unknown
- 2012-02-03 TN TNP2012000054A patent/TN2012000054A1/en unknown
- 2012-02-08 CL CL2012000333A patent/CL2012000333A1/es unknown
- 2012-02-09 ZA ZA2012/00980A patent/ZA201200980B/en unknown
- 2012-03-08 MA MA34671A patent/MA33571B1/fr unknown
- 2012-11-29 HK HK12112305.1A patent/HK1171336A1/zh not_active IP Right Cessation
-
2015
- 2015-03-06 US US14/640,662 patent/US20150352113A1/en not_active Abandoned
- 2015-08-20 HR HRP20150890TT patent/HRP20150890T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1171336A1 (zh) | 利用結合內皮素受體抑製劑治療腦轉移瘤 | |
HK1258401A1 (zh) | T細胞活化的抑制劑 | |
ZA201704808B (en) | Cytotoxic benzodiazepine derivatives | |
HK1175725A1 (zh) | 流體輸送裝置 | |
EP2764885A4 (en) | CATHETER AT HOME | |
EP2379424A4 (en) | INFUSION ASSEMBLY | |
EP2446278A4 (en) | FLUID INJECTION | |
EP2410859A4 (en) | TRANSDERMAL ADMINISTRATION | |
EP2719417A4 (en) | NEEDLE NEEDLE DEVICE | |
PL2512273T3 (pl) | Element składowy wyrobu do palenia | |
ZA201107214B (en) | Delivering liquid additive | |
PL2515632T3 (pl) | Urządzenie do podawania płynu | |
EP2502627A4 (en) | ANTI CANCER AGENTS | |
HK1199729A1 (zh) | 成癮治療中的 抑制劑 | |
IL218495A0 (en) | Theraputic agent for chronic pain | |
GB0917792D0 (en) | Delivery agent | |
EP2408462A4 (en) | TARGETED ADMINISTRATION CHEMOTHERAPEUTIC AGENT | |
ZA201505135B (en) | Cytotoxic benzodiazepine derivatives | |
GB201100101D0 (en) | Fluid loss additive for enhanced fracture clean-up | |
GB201105234D0 (en) | Fluid dynamics flossing and brushing device |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20190812 |